- Home
- FUND vs PROK Comparison
FUND vs PROK Comparison
Compare FUND & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUND
- PROK
- Stock Information
- Founded
- FUND 1988
- PROK 2015
- Country
- FUND Canada
- PROK United States
- Employees
- FUND N/A
- PROK N/A
- Industry
- FUND Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FUND Finance
- PROK Health Care
- Exchange
- FUND Nasdaq
- PROK Nasdaq
- Market Cap
- FUND 236.5M
- PROK 220.6M
- IPO Year
- FUND N/A
- PROK N/A
- Fundamental
- Price
- FUND $8.03
- PROK $1.69
- Analyst Decision
- FUND
- PROK Buy
- Analyst Count
- FUND 0
- PROK 5
- Target Price
- FUND N/A
- PROK $4.50
- AVG Volume (30 Days)
- FUND 32.5K
- PROK 446.4K
- Earning Date
- FUND 01-01-0001
- PROK 11-12-2024
- Dividend Yield
- FUND 6.64%
- PROK N/A
- EPS Growth
- FUND N/A
- PROK N/A
- EPS
- FUND 0.93
- PROK N/A
- Revenue
- FUND N/A
- PROK N/A
- Revenue This Year
- FUND N/A
- PROK N/A
- Revenue Next Year
- FUND N/A
- PROK N/A
- P/E Ratio
- FUND $8.33
- PROK N/A
- Revenue Growth
- FUND N/A
- PROK N/A
- 52 Week Low
- FUND $6.75
- PROK $1.18
- 52 Week High
- FUND $8.47
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- FUND 61.60
- PROK 45.01
- Support Level
- FUND $7.77
- PROK $1.50
- Resistance Level
- FUND $7.89
- PROK $1.81
- Average True Range (ATR)
- FUND 0.09
- PROK 0.20
- MACD
- FUND 0.00
- PROK -0.02
- Stochastic Oscillator
- FUND 78.05
- PROK 24.84
About FUND Sprott Focus Trust Inc.
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.